|Solubility:||DMSO up to 25 mM|
|Storage:||Powder: 4oC 1 year. DMSO: 4oC 3 month; -20oC 1 year.|
LDN-57444 is a novel potent and selective inhibitor of ubiquitin C-terminal hydrolase-L1 (UCH-L1) with IC50 ~0.88 μM. It has ~28-fold greater selectivity over UCH-L3 (ubiquitin C-terminal hydrolase L3). LDN-57444 can increase levels of highly ubiquitinated proteins and decreases ubiquitin proteasome activity. It causes cell death through the apoptosis pathway. LDN-57444’s activity leads to dramatic alterations in synaptic protein distribution and spine morphology in vivo.
How to Use:
- In vitro: LDN-57444 was used at 5-25 µM final concentration in various in vitro assays.
- In vivo: LDN-57444 was administered through IP injection at 0.5 mg/kg in a-syn transgenic mice.
- 1. Gong B, et al. Ubiquitin hydrolase Uch-L1 rescues beta-amyloid-induced decreases in synaptic function and contextual memory. (2006) Cell. 126(4):775-88.
- 2. Liu Y, et al. Discovery of inhibitors that elucidate the role of UCH-L1 activity in the H1299 lung cancer cell line. (2003) Chem Biol. 10(9):837-46.
- 3. Tan YY, et al. Endoplasmic reticulum stress contributes to the cell death induced by UCH-L1 inhibitor. (2008) Mol Cell Biochem. 318(1-2):109-15.
- 4. Cartier AE, et al. Regulation of synaptic structure by ubiquitin C-terminal hydrolase L1. (2009) J Neurosci. 29(24):7857-68.
Products are for research use only. Not for human use.
Payment & Security
Your payment information is processed securely. We do not store credit card details nor have access to your credit card information.